Our CEO, Sara, attended the annual International Consortium on Newborn Sequencing (ICoNS) conference in London.
Our attendance at the event contributes valuable knowledge to our strategy to get treatable leukodystrophies, notably ALD and MLD, on the UK newborn screening programme.
To find out more about our campaign to get ALD added to the UK newborn screening programme: Screen Our Boys
